http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101565646-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5038 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2013-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101565646-B1 |
| titleOfInvention | Compositions for the treatment or prevention of immune diseases comprising inhibitor of oxidized phospholipids |
| abstract | The present invention relates to a pharmaceutical composition for preventing or treating an immunological disease comprising an oxidative phospholipid inhibitor as an active ingredient, wherein the phospholipid activates the inflammatory regulatory complex, activates caspase-1, IL-1?) Expression and secretion. Therefore, the antioxidant phosphatase inhibitor may be used as a therapeutic agent for immunological diseases in which overexpression or hypersecretion of interleukin-1 beta (IL-1 beta) is problematic. Further, the present invention provides a method for inhibiting the expression of interleukin-1 beta Inducing method and an effective method for screening a therapeutic agent for an immunological disease in which overexpression or hypersecretion of interleukin-1 beta (IL-1 beta) is problematic. |
| priorityDate | 2013-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 288.